EMERGENT BIOSOLUTIONS INC. COMMON STOCK

NetDania - New 12 months High: EMERGENT BIOSOLUTIONS INC. COMMON STOCK

02 июл 2024 11:02:06 Источник NetDania Notify

Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

02 июл 2024 08:43:07 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

02 июл 2024 07:13:43 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million

20 июн 2024 06:00:57 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day

06 июн 2024 08:02:45 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

10 май 2024 06:17:11 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports First Quarter 2024 Financial Results

01 май 2024 15:57:22 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

01 май 2024 15:10:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

01 май 2024 10:03:28 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

30 апр 2024 16:26:55 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

22 апр 2024 07:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

28 мар 2024 07:15:03 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

25 мар 2024 07:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

06 мар 2024 15:31:01 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

29 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

21 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

11 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

09 янв 2024 06:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

28 ноя 2023 05:59:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

24 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire